{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T19:42:27Z","timestamp":1794512547929,"version":"4.9.1"},"reference-count":31,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,12,5]],"date-time":"2021-12-05T00:00:00Z","timestamp":1638662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    <jats:italic>TP53<\/jats:italic>\n                    aberrations [del(17p) or\n                    <jats:italic>TP53<\/jats:italic>\n                    mutation] predict poor survival with chemoimmunotherapy in patients with chronic lymphocytic leukaemia (CLL). We evaluated long\u2010term efficacy and safety of first\u2010line ibrutinib\u2010based therapy in patients with CLL bearing\n                    <jats:italic>TP53<\/jats:italic>\n                    aberrations in a pooled analysis across four studies: PCYC\u20101122e, RESONATE\u20102 (PCYC\u20101115\/16), iLLUMINATE (PCYC\u20101130) and ECOG\u2010ACRIN E1912. The pooled analysis included 89 patients with\n                    <jats:italic>TP53<\/jats:italic>\n                    aberrations receiving first\u2010line treatment with single\u2010agent ibrutinib (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200945) or ibrutinib in combination with an anti\u2010CD20 antibody (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200944). All 89 patients had del(17p) (53% of 89 patients) and\/or\n                    <jats:italic>TP53<\/jats:italic>\n                    mutation (91% of 58 patients with\n                    <jats:italic>TP53<\/jats:italic>\n                    sequencing results available). With a median follow\u2010up of 49\u00b78\u2009months (range, 0\u00b71\u201395\u00b79), median progression\u2010free survival was not reached. Progression\u2010free survival rate and overall survival rate estimates at four years were 79% and 88%, respectively. Overall response rate was 93%, including complete response in 39% of patients. No new safety signals were identified in this analysis. Forty\u2010six percent of patients remained on ibrutinib treatment at last follow\u2010up. With median follow\u2010up of four years (up to eight years), results from this large, pooled, multi\u2010study data set suggest promising long\u2010term outcomes of first\u2010line ibrutinib\u2010based therapy in patients with\n                    <jats:italic>TP53<\/jats:italic>\n                    aberrations.\n                  <\/jats:p>\n                  <jats:p>Registered at ClinicalTrials.gov (NCT01500733, NCT01722487, NCT02264574 and NCT02048813).<\/jats:p>","DOI":"10.1111\/bjh.17984","type":"journal-article","created":{"date-parts":[[2021,12,5]],"date-time":"2021-12-05T19:19:36Z","timestamp":1638731976000},"page":"947-953","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Long\u2010term efficacy of first\u2010line ibrutinib treatment for chronic lymphocytic leukaemia in patients with\n                    <i>TP53<\/i>\n                    aberrations: a\u2009pooled analysis from four clinical trials"],"prefix":"10.1111","volume":"196","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2088-0899","authenticated-orcid":false,"given":"John N.","family":"Allan","sequence":"first","affiliation":[{"name":"Weill Cornell Medicine New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tait","family":"Shanafelt","sequence":"additional","affiliation":[{"name":"Stanford University Medical Center Stanford CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Wiestner","sequence":"additional","affiliation":[{"name":"National Heart, Lung, and Blood Institute Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3275-0271","authenticated-orcid":false,"given":"Carol","family":"Moreno","sequence":"additional","affiliation":[{"name":"Hospital de la Santa Creu i Sant Pau Autonomous University of Barcelona Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"Chao Family Comprehensive Cancer Center University of California Irvine Irvine CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianling","family":"Li","sequence":"additional","affiliation":[{"name":"Pharmacyclics LLC, an AbbVie Company Sunnyvale CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Krigsfeld","sequence":"additional","affiliation":[{"name":"Pharmacyclics LLC, an AbbVie Company Sunnyvale CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Dean","sequence":"additional","affiliation":[{"name":"Pharmacyclics LLC, an AbbVie Company Sunnyvale CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inhye E.","family":"Ahn","sequence":"additional","affiliation":[{"name":"National Heart, Lung, and Blood Institute Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,12,5]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1908213"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.187583"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1021"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-546150"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-667675"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature15395"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-539726"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25638"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0602-x"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1795159"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30788-5"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30212-1"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-820910"},{"key":"e_1_2_9_19_1","unstructured":"National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology. B\u2010Cell Lymphomas. Version 2.2021. Plymouth Meeting PA National Comprehensive Cancer Network 2021."},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.019"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2005943"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71182-9"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-017-0007-7"},{"key":"e_1_2_9_25_1","first-page":"5348","article-title":"Response assessment in chronic lymphocytic leukemia treated with novel agents causing an increase in peripheral blood lymphocytes","volume":"119","author":"Hallek M","year":"2012","journal-title":"Blood"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651125"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.10.009"},{"key":"e_1_2_9_28_1","doi-asserted-by":"crossref","unstructured":"Al\u2010SawafO ZhangC RobrechtS TandonM PanchalA FinkA\u2010M et\u00a0al.Venetoclax\u2010obinutuzumab for previously untreated chronic lymphocytic leukemia: 4\u2010year follow\u2010up analysis of the randomized CLL14 study. Presented at: EHA2021 Virtual; June 9\u201317 2021. Abstract S146.","DOI":"10.1002\/hon.49_2880"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0594"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4890"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134280"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.259432"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.17984","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.17984","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.17984","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:06:03Z","timestamp":1692835563000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.17984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,5]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1111\/bjh.17984"],"URL":"https:\/\/doi.org\/10.1111\/bjh.17984","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,5]]},"assertion":[{"value":"2021-08-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}